Vor bio enters into exclusive global license agreement with remegen for late-stage autoimmune asset

-vor bio receives ex-greater china rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global phase 3 development for generalized myasthenia gravis -remegen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties -seasoned biopharma leader, jean-paul kress, md, appointed as chief executive officer and chairman of the board, bringing proven track record in clinical development, commercialization, and strategic growth cambridge, mass., june 25, 2025 (globe newswire) -- vor bio, inc. (nasdaq: vor) and remegen co., ltd.
VOR Ratings Summary
VOR Quant Ranking